Skip to main content

Table 1 Baseline Characteristics

From: The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience

Variables Total (N = 160)
Gender, n (%)
 Male 52 (32.5)
 Female 108 (67.5)
Age (years), median (min-max) 58 (22–78)
NAFLD, n (%)
 Yes 115 (71.9)
 No 45 (28.1)
SIBO, n (%)
 Yes 55 (34.4)
 No 105 (65.6)
Obesity, n (%)
 Yes 107 (66.9)
 No 53 (33.1)
DM, n (%)
 Yes 120 (75)
 No 40 (25)
Dyslipidemia, n (%)
 Yes 129 (80.6)
 No 31 (19.4)
Metabolic Syndrome, n (%)
 Yes 122 (76.3)
 No 38 (23.8)
Central Obesity, n (%)
 Yes 149 (93.1)
 No 11 (6.9)
Fibrosis Degree, n (%)
 F0-F1 89 (77.4)
 F2-F4 26 (22.6)
Steatosis Degree, n (%)
 S0 41 (26.4)
 S1 10 (6.4)
 S2 4 (2.5)
 S3 60 (38.7)
Significant Steatosis, n (%)
 Yes 71 (61.7)
 No 44 (38.3)
  1. SIBO Small Intestinal Bacterial Overgrowth, NAFLD Non-Alcoholic Fatty Liver Disease, DM Diabetes Mellitus, PR Prevalence Ratio, CI Confidence Interval